GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fulcrum Therapeutics Inc (NAS:FULC) » Definitions » Scaled Net Operating Assets

FULC (Fulcrum Therapeutics) Scaled Net Operating Assets : 0.03 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Fulcrum Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Fulcrum Therapeutics's operating assets for the quarter that ended in Sep. 2024 was $21.77 Mil. Fulcrum Therapeutics's operating liabilities for the quarter that ended in Sep. 2024 was $12.57 Mil. Fulcrum Therapeutics's Total Assets for the quarter that ended in Jun. 2024 was $294.26 Mil. Therefore, Fulcrum Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.03.


Fulcrum Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Fulcrum Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulcrum Therapeutics Scaled Net Operating Assets Chart

Fulcrum Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial -0.11 -0.16 -0.05 0.04 0.04

Fulcrum Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.04 0.04 0.03

Competitive Comparison of Fulcrum Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Fulcrum Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulcrum Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fulcrum Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Fulcrum Therapeutics's Scaled Net Operating Assets falls into.



Fulcrum Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Fulcrum Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(21.473-11.68)/226.685
=0.04

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=257.694 - 236.221
=21.473

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=22.501 - 8.629 - 2.192
=11.68

Fulcrum Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(21.774-12.572)/294.256
=0.03

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=279.008 - 257.234
=21.774

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=21.717 - 7.011 - 2.134
=12.572

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulcrum Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Fulcrum Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulcrum Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
26 Landsdowne Street, Cambridge, MA, USA, 02139
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Executives
Greg Tourangeau officer: Controller C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Alex Sapir director, officer: See Remarks C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Alan A Musso officer: Chief Financial Officer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J Gould director, officer: President & CEO C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Santiago Arroyo officer: Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Hayes Melvin H. Iii officer: Chief Operating Officer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Esther Rajavelu officer: Chief Financial Officer 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sonja Banks director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bryan Stuart officer: Chief Operating Officer C/O CIVITAS THERAPEUTICS, INC., 190 EVERETT AVENUE, CHELSEA MA 02150
Christopher Moxham officer: Chief Scientific Officer 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Peter G. Thomson officer: VP Finance & Accounting C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139